All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-11-27T14:33:07.000Z

Lymphoma Hub Satellite Symposium—Summary and roundtable discussion

Bookmark this article

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma.

The symposium brought together a panel of international experts, who gave their opinion on two distinct patient cases, presented in Figure 1. Click to see the presentations by Kieron Dunleavy, Marie José Kersten, Astrid Pavlovsky and Francesc Bosch.

Figure 1. A R/R DLBCL patient case and B R/R CLL patient case

ASCT, autologous hematopoietic stem cell transplantation; BM, bone marrow; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; DHAP, dexamethasone + high-dose cytarabine + cisplatin; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy chain variable region; LDH, lactate dehydrogenase; R-CHOP, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone; R/R, relapsed and/or refractory; WBC, white blood cell. 

Following a diverse selection of presentations by the four panelists, there was an exciting roundtable discussion answering any questions submitted by the audience; watch it below.

Satellite Symposium | Roundtable discussion

In the lead up to the virtual symposium, the Lymphoma Hub conducted a series of Twitter polls to gain insight into the audience’s understanding of, and interests within, the field of R/R lymphoma (Figure 2). Take a look at the Lymphoma Hub symposium content in our Twitter moment.

Figure 2. Results of the Lymphoma Hub Satellite Symposium Twitter polls 

allo-SCT, allogeneic stem cell transplant; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; R/R relapsed and/or refractory. 

Below, Lymphoma Hub Chair Gilles Salles shares the highlights from the symposium.

Highlights of the Lymphoma Hub Satellite Symposium

  1. Lymphoma Hub. How I treat relapsed/refractory disease – DLBCL and CLL. Satellite Symposium. ESH How to Diagnose and Treat: Lymphoma; Nov 8, 2020; Virtual.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox